Ozer Baysal - Agenus Insider

AJ81 -- Germany Stock  

EUR 1.83  0.02  1.10%

Mr. Ozer Baysal is Chief Commercial Officer, Head of HR of Agenus Inc. Mr. Baysal was Chief Business Officer since January 2013 until July 1, 2017. Prior to joining Agenus Mr. Baysal spent more than 30 years with Pfizer in a broad number of functional and geographic areas, most recently serving as President of Europe, Emerging Markets Region. While at Pfizer, he held key leadership positions in Marketing, Sales, and Manufacturing, and was actively involved with numerous licensing and MA activities
Age: 60  Executive Since 2017      
781-674-4400  http://agenusbio.com
Baysal holds a bachelor degree from Bosphorus University in Industrial Engineering and has completed the Programs for Leadership and Management Development at Harvard Business School.

Management Efficiency

The company has return on total asset (ROA) of (48.74) % which means that it has lost $48.74 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (421.01) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 13.47 M in total debt. Agenus has Current Ratio of 2.12 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system to fight cancer. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 255 people.Agenus (AJ81) is traded on Frankfurt Stock Exchange in Germany. It is located in 3 Forbes Road and employs 255 people.

Agenus Leadership Team

Robert Stein, Chief Scientific Officer
James Gorman, Vice President - Strategic Planning and Portfolio Management
Ozer Baysal, Chief Business Officer
Ulf Wiinberg, Director
Shalini Sharp, Director
Wadih Jordan, Independent Director
Christine Klaskin, Principal Financial Officer, Principal Accounting Officer, Vice President - Finance
Garo Armen, Chairman of the Board, CEO
JeanMarie Cuillerot, Chief Medical Officer
Brian Corvese, Independent Director
Andrea Rabney, IR Contact Officer
Karen Valentine, Vice President Chief Compliance Officer, General Counsel, Secretary
Shahzad Malik, Independent Director
Evan Ballantyne, CFO
Timothy Wright, Lead Independent Director

Stock Performance Indicators

Current Sentiment - AJ81

Agenus Investor Sentiment
Macroaxis portfolio users are unresponsive in their sentiment towards investing in Agenus. What is your sentiment towards investing in Agenus? Are you bullish or bearish?
50% Bullish
50% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Agenus and Steris Plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.